Phase 2 trial of montelukast for prevention of pain in sickle cell disease

Cysteinyl leukotrienes (CysLTs) are lipid mediators of inflammation. In patients with sickle cell disease (SCD), levels of CysLTs are increased compared with controls and associated with a higher rate of hospitalization for pain. We tested the hypothesis that administration of the CysLT receptor ant...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood Adv
Prif Awduron: Field, Joshua J., Kassim, Adetola, Brandow, Amanda, Embury, Stephen H., Matsui, Neil, Wilkerson, Karina, Bryant, Valencia, Zhang, Liyun, Simpson, Pippa, DeBaun, Michael R.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2020
Pynciau:
Clinical Trials and Observations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7094028/
https://ncbi.nlm.nih.gov/pubmed/32208487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001165
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg